Trial
NCT04533737
Efficacy and Safety of Brodalumab Compared With Guselkumab in the Treatment of Plaque Psoriasis After Inadequate Response to Ustekinumab
Phase IVTERMINATEDOPERATIONALConfidence: HIGH
Sponsor
LEO Pharma
Collaborators
—
Condition
Plaque Psoriasis
Intervention
Brodalumab
Why stopped
The recruitment was terminated early due to delays and slow recruitment that significantly jeopardized the trial timelines. There were no safety concerns related to the early termination of the trial.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2025-03-14